Bcrp Knockout Rat
Model Detail >
Nomenclature:
SD-
Abcg2
tm1sage
Genotype:
Homozygous
Product number:
TGRS4200
Research Applications
- DMPK
- Efflux assay
- Neurotoxicology
- Formulation
- Blood brain barrier efflux
- Drug-drug interactions
- Tissue distribution
- Efficacy assay
Downloads
File size: 332.29kFile size: 27.4k
Description
BCRP plays a protective role in neurotoxicity by limiting the efflux of xenobiotics into the brain. Homozygous null rats demonstrate increased exposure in the brain and plasma when dosed with BCRP-specific substrates.
Request a quote and a SAGE® Labs research specialist will contact you with an estimated price and delivery date.
Characteristics
- Biallelic 588 bp deletion within Abcg2 gene
- Homozygous knockouts display total loss of protein via Western blot
- Increased oral bioavailability of BCRP-specific substrates
- Sprague-Dawley background strain
Figure 1. Oral absorption of sulfasalazine
Figure 2. Dantrolene level of Bcrp (-/-) and wild type rats 2 hours after treatment (nM/g)
Additional Information
Loss of function of Bcrp leads to improper transport of drugs across epithelial cells and increased bioavailability of Bcrp substrates. This model is useful for studying metabolism of xenobiotic compounds, tissue distribution, DMPK, efficacy, formulation, and blood brain barrier efflux.
Publications
- Zamek-Gliszczynski, M, et al. Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics.
- Zamek-Gliszczynski, M, et al. Characterization of SAGE Labs Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. DMD. 2012
